We found that a combination of KRAS inhibitor, MRTX1133, and venetoclax, in fact, caused the tumors to regress. That, to me, is a clinically meaningful finding that we can take to patients. KRAS inhibitors are being considered for clinical trials, and our hope is that we can add the FDA-approved drug venetoclax to enhance the efficacy of MRTX1133,
Pancreatic cancer is the third most common type of cancer in the U.S. and an estimated 66,440 cases will be diagnosed this year. Despite advances in treatment... the five-year survival rate has continued to hover around just 13 percent, highlighting an urgent need for more effective treatments.
KRAS inhibitors are the new frontier in pancreatic cancer. They may have a big impact, but we also know that resistance will be inevitable. So can we do something to understand resistance mechanisms, and can we develop combination regimens that overcome this issue?
Collection
[
|
...
]